What vital choices did you make at the start of your career?
During my undergraduate studies, there was a time when I thought I would focus on plants. However, a seminar on bacteria entitled "Analysis of Experimental Results", taught by Professor Eliora Ron, transformed my thinking and my dreams. It changed my life. I decided to become a microbiologist.
After completing my PhD, I wanted to continue in microbiology, studying systems of higher cells that resemble human cells. I chose molecular parasitology, focusing on the Great Neglected Diseases, a range of diseases not yet eradicated. To this day I work on pathogenic parasites that affect millions around the world.
Which of your research projects do you consider most important?
I study RNA. Cells of living organisms contain the genetic material DNA, proteins, and messenger RNA (mRNA), which carries information for protein production from the DNA. For many years, RNA was viewed merely as a messenger, while non-coding RNA molecules, that do not carry instructions for protein synthesis, were largely overlooked. I belong to a large group of scientists around the world and a smaller group in Israel, who recognized that RNA also plays a major role in regulating protein synthesis in cells.
In the early 2000s, I started investigating RNA molecules that guide chemical modifications on other RNA molecules. For one of these modifications, called pseudouridine, at the time identified primarily on long-lived RNA molecules, I demonstrated presence on short-lived RNA molecules as well. Years later this modification was incorporated into the mRNA used in COVID-19 vaccines, and was a key factor in their success.
In 2022 I joined Professor Ada Yonath of the Weizmann Institute of Science, awarded the Nobel Prize for deciphering the structure and function of the ribosome - the cellular machine that translates genetic information into protein synthesis. Together we investigated the effects of RNA-guided chemical modifications on the ribosome and its RNA. We showed that even a single modification in the ribosome can alter patterns of protein synthesis, enabling pathogenic parasites to adapt to changes in their environment. This has been one of the most important projects of my career.
Another key focus of my efforts has been the Leishmania parasite that causes the skin disease cutaneous leishmaniasis, commonly known in Israel as the "Jericho Rose" disease. While the disease still affects millions in a hundred countries worldwide, including Israel, no effective, non-toxic, easily accessible treatment is yet available. In fact, many IDF soldiers, stung by sand flies - the transmitting agent, suffered considerably from painful leishmaniasis lesions during the Iron Swords war.
In 2010, together with researchers from TAU, supported by a grant from The Israel National Nanotechnology Initiative (INNI) I began developing a nanotechnology-based treatment for this disease, as well as for sleeping sickness which belongs to the same family. I developed an effective therapeutic ointment called NANO-LISH-IL, which was successfully tested in animals in 2021 and is now undergoing clinical trials. My dream is to bring this treatment to the stage of mass production and make it widely available.
I was also a member of the Rimonim consortium established in 2010 by Israel's Chief Scientist to develop technologies for delivering gene-silencing RNA molecules to cancer cells. Working with TAU researchers Prof. Dan Peer and Prof. Ronit Satchi-Fainaro, we developed a nanocarrier with a polymer that bonds RNA and used it in IP injections, primarily for ovarian cancer. Later I applied this technology to infectious diseases, and I still work on RNA delivery for treating various skin diseases. I believe that RNA control will be an integral part of natural medical therapies. As we saw with the successful COVID vaccine, this is the future!